Territorial Availability: Available through Bertin Technologies only in France
Technical Warning: Bertin Technologies restricts the sale of this product to licensed controlled substance laboratories and qualified academic research institutions. Please contact us for further details.
Special Advice: Please check regulation status before ordering; additionel fees can apply.
- Synonyms
- 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid
- Correlated keywords
- forensics sciences neurosciences cannabinoids CBs JWH 018 5-fluoro-PB22 PB-22 metabolites BB22 BBs 22 BB-22 JWHs 018 JWH-018 JWH018 PB-22 PBs PC22 analogs serum urine potent synthetics derivatives phsychological toxicological toxic research applications 5-flouro 8-hydroxyquinoline carboxyindoles analytical references standards QUCHIC
- Product Overview:
BB-22 (Item No. 14099) is an analog of the potent synthetic cannabinoid, JWH 018 (Item No. 10900) that is structurally similar to PB-22 (Item No. 14096) and its derivative, 5-fluoro PB-22 (Item No. 14095).{18291,19507} Both BB-22 and PB-22 are distinctive in that an 8-hydroxyquinoline replaces the naphthalene group of JWH 018. BB-22 3-carboxyindole metabolite is expected to be a metabolite of BB-22 that would be detectable both in serum and urine. The physiological and toxicological properties of this compound are not known. This product is intended for forensic and research applications.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.